Home - DECISION

News

30 June 2025

Halfway There: COMBAT Hits 50% Recruitment Milestone

We’re proud to share that the COMBAT study, part of the DECISION project, has reached 50% of its recruitment target!

This marks an important moment in our shared effort to advance personalised treatment strategies for acute-on-chronic liver failure (ACLF). Every inclusion brings us closer to actionable insights that can improve patient care.

Our thanks go out to all participating clinical sites and their teams for their continued dedication, as well as to our study participants and their families.

Curious about the COMBAT trial? Our questions and answers videos are available in English, German, Italian, Spanish, and French. Check out the full playlist!

More news

News

26 June 2025

New keynote lecture: Inflammation in AD & ACLF

🎥 Now available to watch!
We’re excited to share the recording of Prof. Dr. Richard Moreau’s keynote lecture on inflammation in acute decompensation (AD) and acute-on-chronic liver failure (ACLF), delivered at the DECISION General Assembly.

Prof. Moreau, Director of EF CLIF, walks us through key terminology, explores the immune dysfunctions characteristic of cirrhosis, and proposes a common mechanism underlying systemic inflammation and immune deficiency in AD and ACLF.

This is a must-watch for anyone interested in liver failure pathophysiology and immune response research.
📺 Watch here 👉 https://youtu.be/KWoUbTsNjQM

More news

Events

9 - 10 April 2025

11th Steering Committee Meeting

Our 11th SC Meeting, took place on 10 April 2025 in Barcelona. These meetings are a key moment in our project timeline, an opportunity to review progress across all work packages, align on next steps, and reconnect in person.

With major updates from both clinical studies and a busy season of dissemination ahead, we had engaging discussions and shared insights that will continue to move DECISION forward.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.